PeptiDream aspires to be a world leader in the discovery and development of novel highly functional peptide therapeutics to address unmet medical needs and improve the quality of life of patients worldwide.

The Next Generation of Radiopharmaceuticals in PDRadiopharma.Inc

Keiichi Masuya Ph.D.

Chief Operating Officer
Member of the Board
PeptiDream Inc
Over 200 employees at current
Partnerships in Three Business Strategies of PeptiDream

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Collaboration</strong></td>
<td><strong>Discovery and Development</strong></td>
<td><strong>PDPS</strong></td>
<td><strong>Tech Transfer/Licensing</strong></td>
<td><strong>In-House/Strategic Discovery and Development</strong></td>
<td><strong>PDPS</strong></td>
<td><strong>Tech Transfer/Licensing</strong></td>
<td><strong>In-House/Strategic Discovery and Development</strong></td>
<td><strong>PDPS</strong></td>
</tr>
<tr>
<td>Bristol-Myers Squibb</td>
<td>AMGEN</td>
<td>SANOFI</td>
<td>TEIJIN</td>
<td>ASAHIKASEI</td>
<td>Bayer</td>
<td>Genentech</td>
<td>Novartis</td>
<td>Merck</td>
</tr>
<tr>
<td><strong>PDC programs</strong></td>
<td><strong>Expanded programs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: Historical footprint for company's press releases related to new alliance/partnership agreement as of Jun 30, 2022. Not including a press release about milestone achievement or progress for each program.
PeptiDream took over 100% of RI business in FUJIFILM

News Release

September 2, 2021

PeptiDream Inc.
https://www.peptidream.com/
(Securities Code: 4587 TSE Section 1)

PeptiDream Agrees to Acquire FUJIFILM Toyama Chemical's Radiopharmaceutical Business from Fujifilm

— Combining PeptiDream's excellence in peptide drug conjugates with the Fujifilm Group's strength as a radiopharmaceutical platform in Japan —

KANAGAWA, JAPAN – September 2, 2021 – PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (“PeptiDream”) (Tokyo:4587), announced today that the Board of Directors has resolved to acquire all outstanding shares of a newly established company (“the New Company”) that succeeds the radiopharmaceutical business (“the acquired business”) of FUJIFILM Toyama Chemical Co., Ltd. (“FUJIFILM Toyama Chemical”) through an absorption-type split, and to make the New Company a subsidiary of PeptiDream (the resolution is hereinafter referred to as “the acquisition”) under the share purchase agreement signed with FUJIFILM Corporation (“Fujifilm”).
Growing reputation as a high-quality manufacturer of GLP/GMP grade peptides

Peptide-CDMO Business (2017-)

<15%

Radiopharma Business (2020-)

5%

Strategic partner in the discovery and development of RI-PDC products
- Lead program scheduled to enter GLP-IND stage in 2022
- PeptiDream has an option to develop and commercialize the joint programs in Japan

Growth factor Business (2020-)

39.5%

Development and commercialization of peptide alternatives to growth factors, and R&D collaborations for therapeutic use
- Two products launched in 2021
- Two additional products launched to date in 2022

PeptiAID COVID-19 Therapeutics (2020-)

39.4%

Advancing potent CoV2 antagonist PA-001 in clinical development

Computational Drug Discovery (2018-)

<5%

Computer aided small molecule drug development of allosteric kinase inhibitors by using peptide starting points
- Lead program scheduled to enter GLP-IND stage in 2022

Established platform for clinical development, approval, marketing and sales of radiopharmaceuticals in Japan
- Acquisition completed on Mar 28, 2022
- Transforming into a quickly profitable, high-growth model
Key Products Portfolio Overview for Radiopharmaceutical area
Currently markets 24 diagnostic products and 8 therapeutic products (3 product categories) in Japan

Diagnostic and Therapeutic RI Products
Target Business provides medical Dx and Tx that are minimally invasive to our body

Diagnostics (Dx): 24 products
- Thyroid Imaging
- Brain Imaging
- Bone Imaging
- Lung Imaging
- Liver Imaging
- Cardiac Imaging
- Kidney Imaging
- Malignant Tumor Imaging

Therapeutics (Tx): 8 products (3 categories)
- Thyroid Therapy
- NHL Therapy
- PPGL Therapy

Key Product Portfolio

<table>
<thead>
<tr>
<th>SPECT</th>
<th>Main Products</th>
<th>Target Diagnosis</th>
<th>PET</th>
<th>Main Products</th>
<th>Target Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OctreoScan®</td>
<td>Somatostatin Receptor Scintigraphy</td>
<td>Amyvid® Injection</td>
<td>Visualization of amyloid beta plaque in the brain</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Techne® MDP</td>
<td>Bone Scintigraphy</td>
<td>Fludeoxyglucose Injection (FDG)</td>
<td>Malignant Tumor/Heart Disease/Intractable Partial Epilepsy/Large-vessel Vasculitis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Neurorite®</td>
<td>Cerebral Blood Flow</td>
<td>Raiatt MIBG-I 131 Injection</td>
<td>MIBG avid Pheochromocytoma/Paraganglioma</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cardiolite®</td>
<td>Heart Disease/Hyperparathyroidism</td>
<td>Zevalin Indium Injection Set</td>
<td>Confirmation of antibody accumulation site</td>
<td></td>
</tr>
<tr>
<td></td>
<td>MyoMIBG®</td>
<td>Heart Disease/Pheochromocytoma</td>
<td>TI201</td>
<td>Heart Disease</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ultra-Technie Kow®</td>
<td>Brain Diseases/Thyroid Disease/Salivary Gland Disease</td>
<td>Zevalin® Yttrium Injection Set</td>
<td>Low-grade non-Hodgkin’s B-cell Lymphoma/Mantle Cell Lymphoma</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sodium Iodide-131 Capsule</td>
<td>Hyperthyroidism/Primary and Metastatic Thyroid Cancer</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NHL: non-Hodgkin’s Lymphoma, PPGL: Pheochromocytoma/Paraganglioma
Note: as of July 2022
Area of R&D in PeptiDream

**Peptide**
- Next-generation PD1/PD-L1 inhibitors
- Drugs for the treatment of COVID-19 and its variants: PA-001
- Growth hormone receptor (GHR) inhibitors: AZP-3813
- Numerous other programs under research and development

**Small molecule**
- Anti-allergic agents
- Other multiple programs under research and development

**PDC (Peptide-Drug Conjugate)**
- Targeted peptides that deliver a therapeutic payload
  - Delivery to Cancer Cells/Tumors: RI-PDC (PDRadiopharma, BMS, RayzeBio, Novartis, Bayer; in negotiations with other major pharmaceutical companies)
  - Delivery of payloads to brain and muscle (Takeda, In negotiations with other major pharmaceutical companies)
  - Delivery of nucleic acid drugs to targeted tissues (Alnylam, negotiating with other major pharmaceutical companies)

**MPC (Multi-functional Peptide Conjugate)**
- Combinations of functional peptides
  - CD38-ARM™: BHV-1100
  - Other programs under expansion
    - Multidrug combinations (two or more agents) that cannot be expressed by Bispecific antibodies are feasible
    - Avoidable immunogenicity/toxicity which is frequently observed in combination therapy of two or several antibodies
    - The development period and cost can be significantly reduced compared to the combination therapy

—
PDPS can identify multiple binders at once
Theoretically we can choose optimal carrier (silent binder vs antagonist) binder for RI-PDC

PDPS Selections

Screening
SPR / cell based assay

Rough characterization of peptides
- Silent binder
- Agonist
- Antagonist

PDB code: 3UG1

PDC*

Drugs

Culture materials

Synergistic impact to many projects and development of products!

* Peptide-Drug Conjugate
Peptide-Drug Conjugate (PDC)
Deliver payloads to the desired tissue/targets using carrier peptides

**Carrier:**
Selectively deliver therapeutic payload to target tissue/cell

**Linker:**
- enzyme recognition site + spacer
- Contributes to the physical characteristics and PK of the entire PDC

**Payload:** Elicit the desired therapeutic response

- **antibody**
  - peptide-antibody conjugate
- **nucleic acid**
  - Antisense oligo (ASO), siRNA heteroduplex oligonucleotide
- **Radionuclide**
  - (diagnosis / therapy)
  - \( ^{111}\text{In} \) \( ^{90}\text{Y} \)
  - Diagnostic / Therapeutic RI
- **peptide**
  - Biologically active peptide as a payload
- **Small molecule, other**
  - Cell / particle, Vaccine, Immunotoxin, Virus

**The advantages of peptides as a carrier**

- Selectively deliver payload
- Variable PK profile by chemical modification
- Full control of drug-ratio
- Diverse molecule combination

**Driving the growth of other modalities through discovery of carrier peptides**

- **Delivery to tumor tissue**
  - Alzheimer's disease, Parkinson's disease, brain tumor
- **Delivery to brain**
  - Advanced / metastatic solid tumor
  - (Pancreatic cancer, lung cancer, prostate cancer, etc.)
- **Delivery to muscle**
  - Muscular dystrophy, myasthenia gravis
- **Other**
**A New treatment that Peptide-drug conjugate (PDC) open up**

Deliver payloads to the desired tissue / targets using carrier peptides

---

### Peptide Drug Conjugate (PDC)

- **Carrier:** Selectively deliver therapeutic payload to target tissue/cell
- **Payload:** Elicit the desired therapeutic response

### Benefits of peptides as carriers

<table>
<thead>
<tr>
<th></th>
<th>ADC</th>
<th>PDC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Selectivity</td>
<td>☐</td>
<td>☐~◎</td>
</tr>
<tr>
<td>Adjustment of human body retention time</td>
<td>△</td>
<td>☐~◎</td>
</tr>
<tr>
<td>Flexibility of payload</td>
<td>△</td>
<td>◎</td>
</tr>
<tr>
<td>Control of the number of payloads</td>
<td>△</td>
<td>◎</td>
</tr>
<tr>
<td>Tumor penetration</td>
<td>△</td>
<td>◎</td>
</tr>
<tr>
<td>Easy to conjugate and production cost</td>
<td>△</td>
<td>◎</td>
</tr>
</tbody>
</table>

---

**Collaboration with Takeda Pharmaceutical Company Limited on neuromuscular and central nervous system diseases**

- **Carrier:** hTfR binding peptide
- **Payload:** Not disclosed

**Collaboration with Alnylam Pharmaceuticals, nucleic acid Therapeutics pioneer and leading company**

- **Carrier:** Target binding peptides
- **Payload:** siRNA

---

- Delivery to **tumor tissue**
- Delivery to **brain / muscle**
- Others
PeptiDream keeps rights of upcoming products in Japan
Delivering the next-generation of targeted radiotherapies through discovery of carrier peptides

RI : Lack targeting function

Highly selective carriers with ideal pharmacokinetic properties are essential

<table>
<thead>
<tr>
<th>Carrier Target</th>
<th>Partner</th>
<th>Development status</th>
<th>JP Rights</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cancer/Tumor Targets</td>
<td>Novartis</td>
<td>Lead to GLP tox</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Multiple programs</td>
<td></td>
</tr>
<tr>
<td>Cancer/Tumor Targets</td>
<td>RayzeBio</td>
<td>GLP tox to PhI</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Multiple programs</td>
<td>✓</td>
</tr>
<tr>
<td>Cancer/Tumor Targets</td>
<td>PeptiDream</td>
<td>Lead to GLP tox</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Multiple programs</td>
<td>✓</td>
</tr>
<tr>
<td>Cancer/Tumor Targets</td>
<td>Global Partners</td>
<td>Lead to GLP tox</td>
<td>PD to retain Japan rights</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Multiple programs</td>
<td>✓</td>
</tr>
</tbody>
</table>

★ PeptiDream to announce targeting peptide and payload when program reaches development candidate decision

PeptiDream continues to grow its peptide-RI conjugate pipeline
Acquisition of PDR Pharma allows PeptiDream to retain development and commercialization rights in Japan

Delivery to cancer cell by targeting tumor-specific target

Conventional RI-Therapy: non-specific
Targeted radiotherapy: specific

Peptide (carrier)  RI (payload)

Irradiation after Imaging (CT)
PD and PDR manage RI-products from Bench to Market
Leveraging clinical data obtained outside Japan for efficient / accelerated development in Japan

Discovery/Optimization | Preclinical Studies | Clinical Development | Manufacturing/Supply Chain | Sales/Marketing

Drug Discovery of RI-PDCs
• Discovery and optimization of carrier peptides / RI-PDCs which deliver radioisotopes to the targeted cells/tissues

Clinical development, manufacturing and sales/marketing outside Japan
• Overseas development and approval may precede domestic process
• Commercialization outside Japan by experts in the respective markets

Development in Japan utilizing overseas data (Bridging/ global study)

Peptide CDMO

Out-license ex-Japan rights

Sales Royalties (to PD)

Out-licensing (to PDR)

Overseas Partners

• Development in Japan utilizing overseas data (Bridging/ global study)

• Clinical trials
• Regulatory filings
• Manufacturing/supply of RI-PDCs
• Sales/marketing

Sales Royalties (to PDR)

etc.
• **Domestic Market:**
  Expand in-house/in-licensing programs including near-term in-licensing of PSMA-RI

• **Global Market:**
  Maximizing value through joint development and out-licensing of in-house programs
Summary
- PeptiDream fully commits Theranostics area in Japan through PDRadiopharma
- PD/PDR could manage a lots of PET and therapeutic RI-drugs with minimum drug-lag
- Domestic Market: Expand in-house/in-licensing programs
- Global Market: Maximizing value through joint development and out-licensing of in-house programs

Thank you for your attention
This presentation contains forward-looking statements. These forward-looking statements are current plans, forecasts, assumptions and strategies based on currently available information. There are various inherent risks as well as uncertainties involved. The actual results of business performance may differ from those forecasts due to various factors.

These factors include, but are not limited to: (1) risks of delays, interruptions or failures associated with drug discovery and development; (2) risks of unexpected program disruptions or terminations due to changes in client policies; (3) risks associated with manufacturing products and the procurement of raw materials; (4) the impact of reduced competitiveness due to the competitors and competing technologies; (5) declining product sales capabilities; (6) adverse rulings in infringements or significant litigation against our Group's intellectual property rights; (7) adverse changes in economic conditions and related laws and regulations; and (8) fluctuations in interest rates and currency exchange rates.

The information in this material with respect to drugs (including those under development) is not intended to provide advertising or medical advice.

This material is intended to provide information on our Group's business and is not intended to solicit investment in securities.

PeptiDream assumes no responsibility for any damages resulting from the use of this material or its content, including without limitation damages related to the use of erroneous information.